Guardian -- A growing number of new drugs for cancer and other conditions are likely to be approved but not reach patients because governments don’t consider them cost effective, the head of Europe’s drugs watchdog said on Friday.
Guardian -- A growing number of new drugs for cancer and other conditions are likely to be approved but not reach patients because governments don’t consider them cost effective, the head of Europe’s drugs watchdog said on Friday.
